Mads E. Bjorn

Roskilde, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.

Journal: Blood cancer journal
Published: May 14, 2024

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.

Journal: Blood advances
Published: March 14, 2024

Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.

Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.

Journal: Acta oncologica (Stockholm, Sweden)
Published: January 18, 2022

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study.

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study.

Journal: Redox biology
Published: December 20, 2020

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Journal: Haematologica
Published: January 16, 2020

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Journal: European journal of haematology
Published: April 29, 2019

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Journal: Leukemia & lymphoma
Published: February 21, 2019

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Journal: Cancer medicine
Published: January 02, 2018

Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.

Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.

Journal: Journal of enzyme inhibition and medicinal chemistry
Published: September 22, 2017

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Journal: Expert review of hematology
Published: April 13, 2017

Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.

Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.

Journal: Arthritis research & therapy
Published: January 12, 2016

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

Journal: The New England journal of medicine
Published: December 25, 2015
Showing 1-12 of 21

Last Updated: 09/26/2026